Skip to main content
Explore URMC

menu

Ocaliva with Liver Cirrhosis

Research Question:
Does Ocaliva improve health outcomes in people with liver cirrhosis?

Basic Study Information

Purpose:
Study participation is a minimum of 1 year, with up to 2 full years of participation possible. Subjects will be randomized to take either 10mg or 25mg of Ocaliva or placebo pill once daily. Subjects must come into the clinic for study related procedures a minimum of 10 times. A liver biopsy is required.

Location: Strong Memorial Hospital
Study Reference #: 20170813

Lead Researcher (Principal Investigator)

Lead Researcher: Jonathan Huang

Study Contact Information

Study Coordinator: Lauren Ott
Phone: (585) 276-3042

Additional Study Details

Study Details:
Sponsored by Intercept Pharmaceuticals

Number of Visits:  More than 10
Parking:  Reimbursed
Transportation Coverage: 
Reimbursement:  Yes

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search